What Frazier Life Sciences does

Frazier Life Sciences is the dedicated biopharmaceutical venture capital arm of Frazier Healthcare Partners, a private healthcare investment firm founded in 1991. The Life Sciences division invests in private and publicly traded companies that discover, develop, and commercialize innovative therapeutics across immunology, oncology, neuroscience, and rare diseases, frequently taking lead investor positions in Series A and B financings and also participating in post-IPO equity rounds and structured private placements. Its core offering is the Frazier Life Sciences Fund — a $1.3 billion dedicated life sciences investment vehicle closed in October 2025, among the largest life-science VC fundraises of 2025 — and the legal entity through which the division operates is Frazier Life Sciences Management, L.P., a Delaware limited partnership.

Within the broader Frazier Healthcare Partners platform, Frazier Life Sciences sits alongside two sibling strategies — Frazier Healthcare Partners Growth Buyout (US middle-market healthcare buyouts) and Frazier Structured Solutions (bespoke structured financing) — together forming a three-pronged healthcare investment platform. The firm is headquartered in Menlo Park with operating offices in Seattle, WA and New York, NY, and runs a lean team of 11–50 professionals.

Frazier Life Sciences' commercial model is institutional venture capital: it raises dedicated fund vehicles from institutional LPs and deploys capital into biopharmaceutical companies, with recent lead and co-lead positions including AirNexis Therapeutics ($200M Series A), cAMPfield Therapeutics ($180M Series A), Sidewinder Therapeutics ($137M Series B, co-led with Novartis Venture Fund), Achieve Life Sciences (up to $354M private placement), Angitia Biopharmaceuticals ($130M Series D), Maze Therapeutics ($115M Series D and $150M post-IPO follow-on), and others. The firm generates revenue through management fees on committed capital and carried interest on realizations (not publicly disclosed), with fund terms and fee structures not publicly available.

Name

Frazier Life Sciences

Legal name

Frazier Life Sciences Management, L.P.

Website

https://frazierhealthcare.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

11–50 employees

Short description

Frazier Life Sciences is the biopharmaceutical venture capital arm of Frazier Healthcare Partners, investing in private and public companies developing innovative therapeutics across immunology, oncology, neuroscience, and rare diseases via a $1.3B life sciences fund.

Ownership category

akta.pro rank

Product category

Life Sciences Venture Capital

NAICS

Scientific Research and Development Services (5417)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Early-Stage Venture Capital (Series A/B) (FSANAAAB)

Keywords

• Biopharmaceutical venture capital
• Life sciences investment
• Healthcare private equity
• Therapeutics funding
• Drug development capital

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Core offering

Frazier Life Sciences is the dedicated biopharmaceutical venture capital arm of Frazier Healthcare Partners. It raises dedicated life sciences fund vehicles from institutional investors and deploys that capital into private and publicly traded companies developing and commercializing innovative biopharmaceuticals, typically leading or co-leading Series A, Series B, Series D, and post-IPO equity financings.

Product overview

Frazier Life Sciences is the dedicated biopharmaceutical investment arm of Frazier Healthcare Partners, operating as a single fund strategy rather than a multi-module software product. Its core offering is the Frazier Life Sciences Fund (a $1.3 billion life sciences investment vehicle) which invests in private and publicly traded companies developing innovative biopharmaceuticals. As part of the broader Frazier Healthcare Partners platform, it sits alongside two sibling strategies — Frazier Healthcare Partners Growth Buyout and Frazier Structured Solutions — together forming the firm's three-pronged healthcare investment platform.

Differentiator

Problem solved

Functional benefit

Products and services

• Frazier Life Sciences Fund

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves7 records

Expansion highlights5 records

Direct peers

• ARCH Venture Partners: A large dedicated life sciences and biotechnology venture capital firm that invests across early- and late-stage therapeutic companies, directly comparable to Frazier Life Sciences in fund scale, sector focus, and lead-investor role.
• Atlas Venture: An early-stage biotech-focused venture capital firm that builds and invests in innovative therapeutics companies; comparable in therapeutic-area focus and lead-investor model, though typically at earlier stages than Frazier.
• RA Capital Management: A healthcare-focused investment firm that invests across public and private biopharma; directly comparable as a peer lead/co-lead in large biotech financings (e.g., co-led Parabilis Medicines' Series F alongside Frazier).
• OrbiMed Advisors: A healthcare-dedicated investment firm with multi-billion-dollar private equity, venture, and public equity funds focused on biopharmaceuticals; directly comparable in AUM scale and therapeutic-stage breadth.
• Versant Ventures: A healthcare-focused venture capital firm investing across biotech, medical devices, and healthcare services; closely comparable as a lead investor in private biopharma financings.
• 5AM Ventures: An early-stage venture capital firm focused on building next-generation life sciences companies; comparable in therapeutic focus and stage of investment.
• Bain Capital Life Sciences: The dedicated life sciences investment platform of Bain Capital, investing across private and public biopharma at scale; comparable in fund size and ability to lead large financings.
• Baker Bros. Advisors: A long-tenured, healthcare-dedicated investment firm focused on public and private biopharmaceutical companies; directly comparable in life sciences focus and willingness to invest across the cap table.

Broad incumbents

• New Enterprise Associates (NEA): One of the world's largest venture capital firms with a significant healthcare and life sciences practice; broadly comparable as a healthcare investor, though NEA invests across technology and healthcare rather than specializing only in biopharma.
• Flagship Pioneering: A bioplatform innovation company that creates and funds breakthrough life sciences ventures; comparable in therapeutic innovation focus but typically originates companies internally rather than investing purely externally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/frazier-healthcare-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments59 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Frazier Life Sciences